文献速递糖尿病肥胖与代谢综合征

他汀治疗对大规模随机盲法他汀试验中新发糖尿病诊断和血糖恶化影响:个体参与者数据荟萃分析

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-03-27

该研究纳入19项他汀与安慰剂对照试验(123940例,中位随访4.3年)和4项强化与常规他汀试验(30724例,中位随访4.9年)。与安慰剂相比,低-中强度他汀使新发糖尿病风险增加10%(RR 1.10,95%CI 1.04-1.16),高强度他汀增加36%(RR 1.36,95%CI 1.25-1.48);基线糖尿病患者血糖恶化风险亦增加。他汀导致剂量依赖性新发糖尿病增加,多数发生在基线血糖接近诊断阈值者。

要点

  • 低-中强度他汀较安慰剂新发糖尿病风险RR 1.10(95%CI 1.04-1.16)。
  • 高强度他汀较安慰剂新发糖尿病风险RR 1.36(95%CI 1.25-1.48)。
  • 基线糖尿病患者血糖恶化:低-中强度他汀RR 1.10,高强度他汀RR 1.24。

核心结论

  • 他汀导致剂量依赖性新发糖尿病诊断适度增加,与血糖小幅上移一致,多数新诊断发生在基线血糖指标接近糖尿病诊断阈值者。
  • 他汀对心血管风险的理论不良影响已被这些试验中观察到的总体心血管风险降低所涵盖。
  • 这些发现应进一步为临床指南关于他汀治疗患者临床管理提供信息。

研究设计与样本

  • 个体参与者数据荟萃分析,纳入参与CTT协作的大规模长期随机双盲他汀试验。
  • 纳入标准为计划 duration 至少2年且至少1000例参与者的双盲随机对照他汀试验。
  • 19项试验比较他汀与安慰剂(123940例,25701例[21%]有糖尿病;中位随访4.3年)。
  • 4项试验比较强化与常规他汀治疗(30724例,5340例[17%]有糖尿病;中位随访4.9年)。
  • 采用预设方案进行逆方差加权荟萃分析。

主要发现

  • 低-中强度他汀组新发糖尿病2420/39179例(每年1.3%)vs 安慰剂组2214/39266例(每年1.2%),RR 1.10(95%CI 1.04-1.16)。
  • 高强度他汀组新发糖尿病1221/9935例(每年4.8%)vs 安慰剂组905/9859例(每年3.5%),RR 1.36(95%CI 1.25-1.48)。
  • 无基线糖尿病者,低-中强度他汀平均血糖升高0.04 mmol/L(95%CI 0.03-0.05),高强度他汀升高0.04 mmol/L(95%CI 0.02-0.06)。
  • 无基线糖尿病者,低-中强度他汀平均HbA1c升高0.06%(95%CI 0.00-0.12),高强度他汀升高0.08%(95%CI 0.07-0.09)。
  • 有基线血糖测量者中约62%新发糖尿病病例位于基线分布最高四分位。

关键数值与推荐

  • 新发糖尿病定义:糖尿病相关不良事件、使用新降糖药物、血糖浓度或HbA1c值。
  • 糖尿病者血糖恶化定义:血糖控制并发症、降糖药物使用增加或HbA1c升高≥0.5%。
  • 基线糖尿病患者血糖恶化:低-中强度他汀RR 1.10(95%CI 1.06-1.14),高强度他汀RR 1.24(95%CI 1.06-1.44)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous meta-analyses of summary data from randomised controlled trials have shown that statin therapy increases the risk of diabetes, but less is known about the size or timing of this effect, or who is at greatest risk. We aimed to address these gaps in knowledge through analysis of individual participant data from large, long-term, randomised, double-blind trials of statin therapy. METHODS: We conducted a meta-analysis of individual participant data from randomised controlled trials of statin therapy that participated in the CTT Collaboration. All double-blind randomised controlled trials of statin therapy of at least 2 years' scheduled duration and with at least 1000 participants were eligible for inclusion in this meta-analysis. All recorded diabetes-related adverse events, treatments, and measures of glycaemia were sought from eligible trials. Meta-analyses assessed the effects of allocation to statin therapy on new-onset diabetes (defined by diabetes-related adverse events, use of new glucose-lowering medications, glucose concentrations, or HbA1c values) and on worsening glycaemia in people with diabetes (defined by complications of glucose control, increased use of glucose-lowering medication, or HbA1c increase of ≥0·5%). Standard inverse-variance-weighted meta-analyses of the effects on these outcomes were conducted according to a prespecified protocol. FINDINGS: Of the trials participating in the CTT Collaboration, 19 trials compared statin versus placebo (123 940 participants, 25 701 [21%] with diabetes; median follow-up of 4·3 years), and four trials compared more versus less intensive statin therapy (30 724 participants, 5340 [17%] with diabetes, median follow-up of 4·9 years). Compared with placebo, allocation to low-intensity or moderate-intensity statin therapy resulted in a 10% proportional increase in new-onset diabetes (2420 of 39 179 participants assigned to receive a statin [1·3% per year] vs 2214 of 39 266 participants assigned to receive placebo [1·2% per year]; rate ratio [RR] 1·10, 95% CI 1·04-1·16), and allocation to high-intensity statin therapy resulted in a 36% proportional increase (1221 of 9935 participants assigned to receive a statin [4·8% per year] vs 905 of 9859 participants assigned to receive placebo [3·5% per year]; 1·36, 1·25-1·48). For each trial, the rate of new-onset diabetes among participants allocated to receive placebo depended mostly on the proportion of participants who had at least one follow-up HbA1c measurement; this proportion was much higher in the high-intensity than the low-intensity or moderate-intensity trials. Consequently, the main determinant of the magnitude of the absolute excesses in the two types of trial was the extent of HbA1c measurement rather than the proportional increase in risk associated with statin therapy. In participants without baseline diabetes, mean glucose increased by 0·04 mmol/L with both low-intensity or moderate-intensity (95% CI 0·03-0·05) and high-intensity statins (0·02-0·06), and mean HbA1c increased by 0·06% (0·00-0·12) with low-intensity or moderate-intensity statins and 0·08% (0·07-0·09) with high-intensity statins. Among those with a baseline measure of glycaemia, approximately 62% of new-onset diabetes cases were among participants who were already in the top quarter of the baseline distribution. The relative effects of statin therapy on new-onset diabetes were similar among different types of participants and over time. Among participants with baseline diabetes, the RRs for worsening glycaemia were 1·10 (1·06-1·14) for low-intensity or moderate-intensity statin therapy and 1·24 (1·06-1·44) for high-intensity statin therapy compared with placebo. INTERPRETATION: Statins cause a moderate dose-dependent increase in new diagnoses of diabetes that is consistent with a small upwards shift in glycaemia, with the majority of new diagnoses of diabetes occurring in people with baseline glycaemic markers that are close to the diagnostic threshold for diabetes. Importantly, however, any theoretical adverse effects of statins on cardiovascular risk that might arise from these small increases in glycaemia (or, indeed, from any other mechanism) are already accounted for in the overall reduction in cardiovascular risk that is seen with statin therapy in these trials. These findings should further inform clinical guidelines regarding clinical management of people taking statin therapy. FUNDING: British Heart Foundation, UK Medical Research Council, and Australian National Health and Medical Research Council.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024. PMID: 38554713. doi:10.1016/S2213-8587(24)00040-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。